GlaxoSmithKline is succeeding with newly launched products and strong R&D flow while struggling with U.S. pricing and competitive pressures.
The industry’s patent cliffs have become less steep, but the Affordable Care Act will give pharma new challenges.
The last few months have seen two major shifts for Bristol-Myers Squibb – out of diabetes and into immuno-oncologics.
AstraZeneca’s efforts to rebuild its pipeline and invest in its growth platforms attracted Pfizer’s notice, with an unsolicited bid of acquisition.
Bolstered by company-record sales, innovative blockbuster products, successful M&A activity, and a pipeline of medicines with breakaway potential, Amgen becomes the first biotech entity to be recognized by Med Ad News as its Company of the Year.
The world’s largest generics company has emerged from the past year with a new CEO, a new organizational structure, and a newly improved bottom line.
Sanofi is trying to bounce back from 2013’s patent cliff with the help of one of the industry’s most diverse product portfolios.
Concentration on targeted medicines and diagnostic tests has enabled Roche to expand its strong market position and significantly improve net income.
For many women who want to advance to leadership in the pharmaceutical industry, the HBA provides the essential tools, backed by its members and corporate partners.
Pfizer stuck to its priorities, but the company’s attempt to buy AstraZeneca fell flat.
